If an eligible patient dies while being treated with an investigational drug, biological product, or device, the eligible patient's heirs are not liable for any outstanding debt related to the treatment, including any costs attributed to lack of insurance coverage for the treatment. HISTORY: 2016 Act No. 230 (H.4542), Section 2, eff June 3, 2016.
South Carolina Legal Code